This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-02. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Individuals whose willingness to volunteer in a clinical trial may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate. Examples are members of a group with a hierarchical structure, such as medical, pharmacy, dental, and nursing students, subordinate hospital and laboratory personnel, employees of the pharmaceutical industry, members of the armed forces, and persons kept in detention. Other vulnerable subjects include patients with incurable diseases, persons in nursing homes, unemployed or impoverished persons, patients in emergency situations, ethnic minority groups, homeless persons, nomads, refugees, minors, and those incapable of giving consent. (ICH E6)
Older infants can suffer a more severe disorder with vomiting, diarrhoea that may be bloody, anemia, weight loss and failure to thrive. The most common cause of this unusual disorder is a sensitivity to cow's milk, but soy formulas can also be the trigger. The precise mechanism is unclear and it could be immunologic, although not through the IgE-type antibodies that have the leading role in urticaria and anaphylaxis. However, it is also self-limiting and will often disappear in the toddler years. In the European Union, identifying the presence of soy either as an ingredient or unintended contaminant in packaged food is compulsory. The regulation (EC) 1169/2011 on food-labeling lists 14 allergens, including soy, in packaged food must be clearly indicated on the label as part of the list of ingredients, using a distinctive typography (such as bold type or capital letters).
anomer Either of a pair of cyclic hemiacetal or hemiketal saccharides that are epimers of each other, differing at only one carbon stereocenter, specifically the carbon that bears the aldehyde or ketone functional group in the compound's acyclic, open-chain configuration, known as the anomeric carbon.
Sam Camfield. Design Manager, South Western Railway. For services to the State Funeral of Her Majesty Queen Elizabeth II. William Wright Glover Campbell. Captain, 1st Stewarton Boys' Brigade. For services to the community in Stewarton, East Ayrshire. Bronwin Mary Carter. Paralympic Coach. For services to Sport. Christopher Charles Cassidy. Watchkeeper, Cabinet Office. For services to Civil Contingencies and to St John Ambulance. Ann Chapman. For services to the community in Radcliffe, Metropolitan Borough of Bury. Stephen Charnock. For services to the community in Newark, Nottinghamshire. Ian Raymond Clark. For services to the community in High Wycombe, Buckinghamshire. Roy Michael Claxton. Founder, Parkinson's Scottish Table Tennis Association. For services to People with Parkinson's Disease. Peter Stewart Clemson. Founder and Chair, Little Theatre Company. For services to the Performing Arts and to the community in Burton-on-Trent, Staffordshire. Judith Mary Climer. Founder, Michael Climer Legacy Fund. For services to the community in Caerphilly. Isobel Jennifer Clink. For services to Golf. Joy Henrietta Mary Coalter. Lately Building and Cleaning Supervisor, Brookeborough Primary School, County Fermanagh. For services to Education. Robert Coburn. Scottish Area Vice Chair, Royal Naval Association and Poppy Appeal Convenor. For voluntary service to Veterans and to the community in Inverness-shire (to be dated 27th November 2023). Dr Shara Cohen. Chief Executive Officer, Honnao Ltd. For voluntary services to Women in STEM and to Cancer Patients and their Families.
Sources: en.wikipedia.org
direct zoonotic transmission to humans (spillover), assessed as "possible to likely" introduction through an intermediate host followed by a spillover, assessed as "likely to very likely" introduction through the (cold) food chain, assessed as "possible" introduction through a laboratory incident, assessed as "extremely unlikely" The report mentions that direct zoonotic transmission to humans has a precedent, as most current human coronaviruses originated in animals. Zoonotic transmission is also supported by the fact that RaTG13 binds to hACE2, although the fit is not optimal. The investigative team noted the requirement for further studies, noting that these would "potentially increase knowledge and understanding globally."
In Blood Diamond, DiCaprio starred as a diamond smuggler from Rhodesia who is involved in the Sierra Leone Civil War. While filming, he worked with 24 orphaned children from the SOS Children's Village in Maputo, Mozambique, and said he was touched by his interactions with them. To prepare, he spent six months in Africa, learned about camouflage from people in South African military and interviewed and recorded people in the country to improve his accent. The film received generally favorable reviews, and DiCaprio was noted for his South African accent, which is generally known as difficult to imitate. Claudia Puig of the USA Today approvingly highlighted DiCaprio's transition from a boy to a man on screen, and Ann Hornaday of The Washington Post similarly noted his growth as an actor since The Departed. DiCaprio received nominations for an Academy Award and a Golden Globe for Blood Diamond. In 2007, DiCaprio produced the comedy drama Gardener of Eden, which according to The Hollywood Reporter's Frank Scheck "lack[ed] the necessary dramatic urgency or black humor to connect with audiences". Later that year, he produced, co-wrote and narrated The 11th Hour, a documentary on the state of the natural environment that won the Earthwatch Environmental Film Award in 2008. DiCaprio's Appian Way produced Planet Green's Greensburg (2008–2010), which ran for three seasons. Set in Greensburg, Kansas, it is about rebuilding the town in a sustainable way after being hit by the 2007 Greensburg tornado.
== Differential diagnosis == The symptoms of Morvan's Syndrome have been noted to bear a striking similarity to limbic encephalitis (LE). These include the CNS symptoms consisting of insomnia, hallucinations, and disorientation, as well as dementia and psychosis. Both entities can be paraneoplastic and associated with thymoma. Recently, VGKC antibodies were found in patients with LE, strengthening the hypothesis that LE and Morvan's Syndrome may be closely connected. Varying symptoms may be used to determine which of the two diseases the subject has. Amnesia, seizures, and mesial temporal lobe structural abnormalities are features of LE, whereas myokymia, hyperhydrosis, and insomnia favor Morvan's Syndrome.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.